Dare Bioscience Inc

NASDAQ:DARE

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2014-04-10. The firm is focused on advancing products for women's health. The company offers a portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. Its first product, XACIATO, is a vaginal gel used for the treatment of bacterial vaginosis in females having 12 years of age and older. Its pipeline includes various other clinical-stage programs, such as Ovaprene, Sildenafil Cream, 3.6%, DARE-HRT1, DARE-VVA1, DARE-FRT1, and DARE-PTB1. Its pre-clinical-stage programs include DARE-LARC1, DARE-RH1, ADARE-204, and ADARE-214. Ovaprene, is an investigational hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a proprietary cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder.